EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats

Critical Care Medicine

Volumn 37, Issue 5, 2009, Pages 1744-1749

  Muto, Yuko ^a   Suzuki, Kokichi ^a   Iida, Hiroyuki ^a   Sakakibara, Shiro ^a   Kato, Emiko ^a   Itoh, Fumi ^a   Kakui, Nobukazu ^a   Ishii, Hidemi ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Fibrinolysis; Organ dysfunction; Plasma carboxypeptidase B; Sepsis; TAFIa inhibitor; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ASPARTATE AMINOTRANSFERASE; CEFTAZIDIME; EF 6265; FIBRIN; FIBRINOGEN; HEPARIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENDOTOXEMIA; FIBRIN DEPOSITION; FIBRINOGEN BLOOD LEVEL; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; RAT; SEPSIS; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

AMINO ACIDS; ANALYSIS OF VARIANCE; ANIMALS; BLOOD CHEMICAL ANALYSIS; CARBOXYPEPTIDASE U; CEFTAZIDIME; DISEASE MODELS, ANIMAL; FIBRINOGEN; HEPARIN; INTERLEUKIN-6; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; MULTIPLE ORGAN FAILURE; PHOSPHINIC ACIDS; PLATELET COUNT; PROBABILITY; PSEUDOMONAS INFECTIONS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; SEPSIS; STEM CELLS;

EID: 67650470216     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819ffc14     Document Type: Article

References (35)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Rice TW, Bernard GR: Therapeutic intervention and targets for sepsis. Annu Rev Med 2005; 56:225-248
3. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-873
4. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005; 365:63-78
5. Leurs J, Hendriks D: Carboxypeptidase U (TAFIa): A metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94:471-487
6. Bouma BN, Meijers JC: Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1:1566-1574
7. Suzuki K, Muto Y, Fushihara K, et al: Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpro-panoylamino)propyl] hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004; 309:607-615
8. Muto Y, Suzuki K, Sato E, et al: Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003; 461:181-189
9. Wang X, Smith PL, Hsu MY, et al: Murine model of ferric chloride-induced vena cava thrombosis: Evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost 2006; 4:403-410
10. Kremer Hovinga JA, Franco RF, Zago MA, et al: A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2004; 2:54-57
11. Watanabe R, Wada H, Watanabe Y, et al: Activity and antigen levels of thrombinactivatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104:1-6
12. Binette TM, Taylor FB Jr, Peer G, et al: Thrombin-thrombomodulin connects coagulation and fibrinolysis: More than an in vitro phenomenon. Blood 2007; 110:3168-3175
13. Sato T, Miwa T, Akatsu H, et al: Procarboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165:1053-1058
14. Nagashima M, Yin ZF, Zhao L, et al: Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109:101-110
15. Asai S, Sato T, Tada T, et al: Absence of procarboxypeptidase R induces complementmediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004; 173: 4669-4674
16. Renckens R, Roelofs JJ, ter Horst SA, et al: Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175: 6764-6771
17. Lenfors S, Gustafsson D: New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: Effects of thrombin inhibitors. Semin Thromb Hemost 1996; 22:335-342
18. Muto Y, Suzuki K, Iida H, et al: EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis. Nephron Exp Nephrol 2007; 106:e113-e121
19. Muto Y, Takata T, Kawabata T, et al: Efficacy of biapenem, meropenem, and ceftazidime in improvement of organ dysfunction in an experimental sepsis model caused by Pseudomonas aeruginosa. [In Japanese] Chemotherapy 2004; 52:209-213
20. Zeerleder S, Hack CE, Wuillemin WA: Disseminated intravascular coagulation in sepsis. Chest 2005; 128:2864-2875
21. Esmon CT: Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32(Suppl 1):49-60
22. Tapper H, Herwald H: Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood 2000; 96:2329-2337
23. Zeerleder S, Schroeder V, Hack CE, et al: TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118:205-212
24. Mutch NJ, Thomas L, Moore NR, et al: TAFIa, PAI-1 and alpha-antiplasmin: Complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 5:812-817
25. Mosnier LO, Meijers JC, Bouma BN: Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85:5-11
26. Liaw PC: Endogenous protein C activation in patients with severe sepsis. Crit Care Med 2004; 32:S214-S218
27. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation 2004; 109:2698-2704
28. Remick DG, Bolgos G, Copeland S, et al: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immunol 2005; 73:2751-2757
29. Deitch EA: Animal models of sepsis and shock: A review and lessons learned. Shock 1998; 9:1-11
30. Lepper PM, Held TK, Schneider EM, et al: Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 2002; 28:824-833
31. Kirikae T, Nakano M, Morrison DC: Antibiotic-induced endotoxin release from bacteria and its clinical significance. Microbiol Immunol 1997; 41:285-294
32. Opal SM, Esmon CT: Bench-to-bedside review: Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 7:23-38
33. Tyrrell DJ, Horne AP, Holme KR, et al: Heparin in inflammation: Potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46:151-208
34. Tanaka T, Tsujinaka T, Kambayashi J, et al: The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb Res 1990; 60:321-330
35. Coalson JJ, Benjamin B, Archer LT, et al: Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circ Shock 1978; 5:423-437